We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Bioxyne is a biotechnology business based in Australia. Bioxyne shares (BXN) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Bioxyne has a trailing 12-month revenue of around $2.4 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $0.011 - $0.036 |
|---|---|
| 50-day moving average | $0.0151 |
| 200-day moving average | $0.0212 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.013
| 1 week (2022-06-17) | 0.013 |
|---|---|
| 1 month (2022-05-26) | -7.14% |
| 3 months (2022-03-25) | -23.53% |
| 6 months (2021-12-24) | -50.00% |
| 1 year (2021-06-25) | -58.06% |
|---|---|
| 2 years (2020-06-26) | 18.18% |
| 3 years (2019-06-26) | -18.75% |
| 5 years (2017-06-26) | -18.75% |
Valuing Bioxyne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioxyne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bioxyne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $162,174 (£91,407).
The EBITDA is a measure of a Bioxyne's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.4 million |
|---|---|
| Operating margin TTM | 6.26% |
| Gross profit TTM | $1.2 million |
| Return on assets TTM | 3.07% |
| Return on equity TTM | -9.88% |
| Profit margin | -8.73% |
| Book value | 0.003 |
| Market capitalisation | $8.3 million |
TTM: trailing 12 months
We're not expecting Bioxyne to pay a dividend over the next 12 months.
Bioxyne's shares were split on a 1:20 basis on 19 March 2012. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Bioxyne shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bioxyne shares which in turn could have impacted Bioxyne's share price.
Over the last 12 months, Bioxyne's shares have ranged in value from as little as $0.011 up to $0.036. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Bioxyne's is 1.47. This would suggest that Bioxyne's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Bioxyne Limited, a life sciences and health products company, engages in the research and development, manufacture, and distribution of probiotic active pharmaceutical ingredients, wellbeing and nutritional supplements, and beauty products. The company operates in two segments, Wholesale Sales and Direct Sales. It engages in developing various functional foods and beauty products. The company's products portfolio includes Progastrim PCC, a proprietary probiotic, for general health and immune support; Mymana and ColosNZ, are colostrum and fortified milks for nutrition and immune support; BK18, a dairy based formula with probiotics and vitamins; Allura, a weight management and beauty drink for women; Mustang, a weight management and vitality shake for men; and BEssence, offers beauty range products comprising anti-ageing serum. Bioxyne Limited also offers foaming and toning cleanser, repair oils, and Progastrim, a probiotic dietary supplement for gut and immune health. The company provides its products online, as well as through wholesale and direct sales in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Steps to owning and managing Kincora Copper shares.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
